C-Suite Snippets: Genomic Medicine Is Coming Of Age
In case you missed it: catch up with snippets from interviews published by In Vivo this week.
You may also be interested in...
Genomic medicine is coming of age. For Illumina chief scientific officer David Bentley, that not only means improved technology, accuracy and coverage of gene sequencing and a broadening into cancer, but also a better understanding among the wider population of disease and precisely the benefits that gene sequencing can bring to patients – actual and pre-symptomatic.
In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2021. Data provided by Biomedtracker.
Deal-making and financing activities are on the rise for liquid biopsy diagnostic products in 2021 despite questions remaining around whether the technology can unseat standard-of-care biomarker and imaging tests.